BIO-Europe, Messe Wien

BIO-Europe Vienna: Successful Partnering for CANTREAT – and a Clear Signal for Our Mission

Successful partnering for CANTREAT at BIO-Europe in Vienna: Productive 1:1 meetings, concrete follow-ups with development partners, and strategic investor discussions on financing, scaling, and study planning.

The financial potential of CANTREAT

/
0 Comments
According to the European Cancer Information System (ECIS), there were 2.68 million new cancer cases in the EU in 2020 (Austria: 44,294, Germany: 538,140).

Cancer – Numbers and facts

/
0 Comments
Cancer is one of the most frightening diagnoses today and the numbers continue to rise!

CANTREAT – Medical device or pharmaceutical?

/
0 Comments
CANTREAT is classified as a medical device: it does not act pharmacologically but serves as a precise distribution method that receives physician-defined pharmaceuticals, transports them to the targeted site, and retains them there.

Chemotherapy – The status today

/
0 Comments
CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery. CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery.

The USP of the CANTREAT-Method

/
0 Comments
CANTREAT consolidates proven approaches from globally researched drug targeting and, with patent-pending components, new materials, and innovative techniques, delivers an efficient, low-side-effect, locally targeted therapy without costly apparatus—a medical novelty with revolutionary potential.

Tyrolean State Prize for Science awarded to Prof. Dr. Andreas Bernkop-Schnürch

Every year, the province of Tyrol honors a personality from three alternating disciplines who has made outstanding achievements in the field of research and science.

Cooperation with the MED-UNI in Innsbruck is working

/
0 Comments
Together with the Institute of Pharmacy at the Leopold-Franzens University of Innsbruck, the basis for the two most essential research topics considered as USP is being developed in a project funded by the Province of Tyrol.